Aurora Investment Counsel’s ANI Pharmaceuticals ANIP Stock Holding History

Aurora Investment Counsel’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+26,890	New	+$2.16M	1.15%	34

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aurora Investment Counsel's ANIP Position: Q2 2026 in Review

Aurora Investment Counsel opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 26,890 shares worth $2.23M. The stake represents 1.15% of the portfolio and ranks #34 among its holdings.

307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Aurora Investment Counsel held 26,890 shares of ANI Pharmaceuticals worth $2.23M as of Q2 2026.
ANI Pharmaceuticals was a new Aurora Investment Counsel position in Q2 2026.
ANI Pharmaceuticals made up 1.15% of Aurora Investment Counsel's portfolio in Q2 2026, its #34 holding.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Aurora Investment Counsel's 13F filing for Q2 2026, filed 10 Aug 2026.